MARKET

MBRX

MBRX

Moleculin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.960
-0.010
-0.34%
After Hours: 2.930 -0.03 -1.01% 17:14 09/24 EDT
OPEN
2.930
PREV CLOSE
2.970
HIGH
3.010
LOW
2.920
VOLUME
98.18K
TURNOVER
--
52 WEEK HIGH
8.78
52 WEEK LOW
2.700
MARKET CAP
84.51M
P/E (TTM)
-3.1945
1D
5D
1M
3M
1Y
5Y
Moleculin Biotech To Present At Oppenheimer Fall Healthcare Life Sciences, MedTech Summit Sept. 20 At 4:35 p.m. EDT
Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that
Benzinga · 09/17 12:08
Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
/PRNewswire/ -- , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that  of Moleculin, will present at the virtual Op...
PR Newswire - PRF · 09/17 12:05
Moleculin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
/PRNewswire/ --, (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that  of Moleculin, will present at the virtual  Co...
PR Newswire - PRF · 09/08 12:01
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
BRIEF-Moleculin Reports Q2 Financial Results
reuters.com · 08/12 12:37
BRIEF-Moleculin Biotech Reports Quarterly Loss Per Share Of $0.15
reuters.com · 08/12 12:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MBRX. Analyze the recent business situations of Moleculin through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MBRX stock price target is 19.00 with a high estimate of 29.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 53
Institutional Holdings: 3.25M
% Owned: 11.38%
Shares Outstanding: 28.55M
TypeInstitutionsShares
Increased
7
752.81K
New
9
178.71K
Decreased
2
301
Sold Out
6
105.92K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
  • All
  • Financials
  • Insiders
More
About MBRX
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of resistant cancers and viruses through the development of its drug candidates. The Company has three product pipelines: Annamycin, WP1066 and WP1122. Annamycin is developed for the treatment of relapsed or refractory acute myeloid leukemia (AML). WP1066 is a immune or transcription modulators capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1α. WP1122 is a prodrug of 2-deoxy-D-glucose (2-DG), which provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells.

Webull offers kinds of Moleculin Biotech Inc stock information, including NASDAQ:MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.